SCHEMBL3023208

SCHEMBL3023208

N#CC1(c2ccccc2)CCC(OCC2CC2)(c2ccc(F)cn2)CC1

nearest known ligand 0.37

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.37
FFAR4 Q5NUL3 2/20 0.35
ALDH2 P05091 1/20 0.35
ALDH1A3 P47895 1/20 0.35
CYP2D6 P10635 1/20 0.35
OPRM1 P35372 1/20 0.34
GRM2 Q14416 1/20 0.34
KDM1A O60341 1/20 0.34
BDKRB1 P46663 1/20 0.34
JAK2 O60674 1/20 0.34
JAK1 P23458 1/20 0.34
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
PTGIR P43119 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3023204 1.00 ALDH1A1 (0.37) ALDH1A1FFAR4ALDH2ALDH1A3CYP2D6
SCHEMBL3023207 1.00 ALDH1A1 (0.37) ALDH1A1FFAR4ALDH2ALDH1A3CYP2D6
SCHEMBL3010220 0.94 FFAR4 (0.35) ALDH1A1FFAR4CYP2D6KDM1ABDKRB1
SCHEMBL3010226 0.94 FFAR4 (0.35) ALDH1A1FFAR4CYP2D6KDM1ABDKRB1
SCHEMBL3010223 0.94 FFAR4 (0.35) ALDH1A1FFAR4CYP2D6KDM1ABDKRB1
SCHEMBL3014300 0.84 ALDH1A1 (0.43) ALDH1A1FFAR4CYP2D6OPRM1GRM2
SCHEMBL3023673 0.81 PTGIR (0.39) OPRM1PTGIR
SCHEMBL3023669 0.81 PTGIR (0.39) OPRM1PTGIR
SCHEMBL3023671 0.81 PTGIR (0.39) OPRM1PTGIR
SCHEMBL3025389 0.79 OPRL1 (0.41) OPRM1PTGIR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2164825-B1 DI(HETERO)ARYLCYCLOHEXANE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM SANOFI SA (FR) 2014-04-30 EP disclosed
US-8076324-B2 Di(hetero)arylcyclohexane derivatives, their preparation, their use and pharmaceutical compositions comprising them SANOFI-AVENTIS (FR) 2011-12-13 US disclosed
US-20100204206-A1 Di(hetero)arylcyclohexane derivatives, their preparation, their use and pharmaceutical compositions comprising them SANOFI-AVENTIS (FR) 2010-08-12 US disclosed
EP-2164825-A1 DI(HETERO)ARYLCYCLOHEXANE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM Sanofi-Aventis (FR) 2010-03-24 EP disclosed
WO-2008148468-A1 DI(HETERO)ARYLCYCLOHEXANE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM SANOFI-AVENTIS (FR) 2008-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204206-A1 Di(hetero)arylcyclohexane derivatives, their preparation, their use and pharmaceutical compositions comprising them ATP2A1, ATP2A2, RYR2 ALDH1A1 1662/4885FFAR4 2512/4885ALDH2 996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.